JPMorgan Lowers Target Price for US Physical Therapy to $110.00, Maintains Overweight Rating

Summary

JPMorgan has reduced its target price for US Physical Therapy, Inc (NYSE: USPH) from $120.00 to $110.00 but maintains an ‘overweight’ rating. This new target suggests a potential 42.73% upside from the previous day’s closing price. Other analysts have varied opinions, ranging from sell to strong buy. The stock is currently traded at $77.07, with a market consensus rating of ‘moderate buy’ and a target price of $109.00. US Physical Therapy’s quarterly earnings per share were reported at $0.65, below expectations, though revenue exceeded expectations at $180.45 million.Market Beat

Impact Analysis

The event is at the company level, specifically affecting US Physical Therapy, Inc. The downward revision of the target price could indicate JPMorgan’s reassessment of the company’s future earnings potential or risks. Key information nodes involve company earnings reports and market analyst ratings. First-order effects include potential adjustments in investor sentiment and stock valuations, with immediate impacts on USPH’s trading price. Second-order effects might involve broader implications for investor confidence in the healthcare and physical therapy sectors. Investment opportunities include reevaluating positions in USPH, considering analyst ratings, and monitoring sector performance for any ripple effects.Market Beat